\n| \n Q3 Performance Summary<\/span><\/b><\/p>\n<\/td>\n | | \n\n 9M Performance Summary<\/span><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n \n\u00a0\n<\/p>\n<\/td>\n | | \n\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n Rs. 4,930 Cr<\/i><\/b><\/p>\n<\/td>\n | | \n\n Rs. 14,244 Cr<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n Revenue<\/i><\/b><\/p>\n<\/td>\n | | \n\n Revenue<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n [Up: 12% YoY; 1% QoQ]<\/i><\/p>\n<\/td>\n | | \n\n [Up: 9% YoY]<\/i><\/p>\n<\/td>\n<\/tr>\n\n| \n \n\u00a0\n<\/p>\n<\/td>\n | | \n\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n 53.8%<\/i><\/b><\/p>\n<\/td>\n | | \n\n 54.6%<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n Gross Margin<\/i><\/b><\/p>\n<\/td>\n | | \n\n Gross Margin<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n [Q3 FY20: 54.1%; Q2 FY21: 53.9%]<\/i><\/p>\n<\/td>\n | | \n\n [9M FY20: 54.7%]<\/i><\/p>\n<\/td>\n<\/tr>\n\n| \n \n\u00a0\n<\/p>\n<\/td>\n | | \n\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n Rs.1,439 Cr<\/i><\/b><\/p>\n<\/td>\n | | \n\n Rs. 4,028 Cr<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n SGNA expenses<\/i><\/b><\/p>\n<\/td>\n | | \n\n SGNA expenses<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n [Up: 14% YoY; 10% QoQ]<\/i><\/p>\n<\/td>\n | | \n\n [Up: 6% YoY]<\/i><\/p>\n<\/td>\n<\/tr>\n\n| \n \n\u00a0\n<\/p>\n<\/td>\n | | \n\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n Rs. 411 Cr<\/i><\/b><\/p>\n<\/td>\n | | \n\n Rs. 1,245 Cr<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n R&D expenses<\/i><\/b><\/p>\n<\/td>\n | | \n\n R&D expenses<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n [8.3% of Revenues]<\/i><\/p>\n<\/td>\n | | \n\n [8.7% of Revenues]<\/i><\/p>\n<\/td>\n<\/tr>\n\n| \n \n\u00a0\n<\/p>\n<\/td>\n | | \n\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n Rs. 1,185 Cr<\/i><\/b><\/p>\n<\/td>\n | | \n\n Rs. 3,615 Cr<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n EBITDA<\/i><\/b><\/p>\n<\/td>\n | | \n\n EBITDA<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n [24.0% of Revenues]<\/i><\/p>\n<\/td>\n | | \n\n [25.4% of Revenues]<\/i><\/p>\n<\/td>\n<\/tr>\n\n| \n \n\u00a0\n<\/p>\n<\/td>\n | | \n\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n Rs. 284 Cr*<\/i><\/b><\/p>\n<\/td>\n | | \n\n Rs. 2,025 Cr<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n Profit before Tax<\/i><\/b><\/p>\n<\/td>\n | | \n\n Profit before Tax<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n [5.8% of Revenues]<\/i><\/p>\n<\/td>\n | | \n\n [14.2% of Revenues]<\/i><\/p>\n<\/td>\n<\/tr>\n\n| \n \n\u00a0\n<\/p>\n<\/td>\n | | \n\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n Rs. 20 Cr**<\/i><\/b><\/p>\n<\/td>\n | | \n\n Rs. 1,361 Cr<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n Profit after Tax<\/i><\/b><\/p>\n<\/td>\n | | \n\n Profit after Tax<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n [0.4% of Revenues]<\/i><\/p>\n<\/td>\n | | \n\n [9.6% of Revenues]<\/i><\/p>\n<\/td>\n<\/tr>\n<\/table>\n *Excluding the impairment charge in Q3 FY21, the Profit before Tax is Rs. 882 cr
\n
**Q3 FY21 Profit after Tax was impacted primarily due to non-recognition of deferred tax asset on impairment<\/i><\/p>\n Commenting on the results, Co-chairman & MD, G V Prasad said, \u201cWe continued with our growth momentum while maintaining EBITDA margins. The profits were impacted due to trigger based impairment charge taken on a few acquired products including Nuvaring. We are progressing well on the phase 3 clinical trials for Sputnik V vaccine in India. We continue to focus on enhancing our product offerings to our patients to serve them better.\u201d<\/i><\/p>\n All amounts in millions, except EPS. All US dollar amounts based on convenience translation rate of I USD = Rs. 73.01<\/i><\/p>\n\n\n| \n Dr. Reddy\u2019s Laboratories Limited and Subsidiaries<\/span><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n Consolidated Income Statement<\/b><\/p>\n<\/td>\n<\/tr>\n\n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| \n Particulars<\/b><\/p>\n<\/td>\n | \n Q3 FY21<\/b><\/p>\n<\/td>\n | \n Q3 FY20<\/b><\/p>\n<\/td>\n | \n YoY
\n
Gr %<\/b><\/p>\n<\/td>\n | \n Q2 FY21<\/b><\/p>\n<\/td>\n | \n QoQ
\n
Gr %<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n ($) <\/b><\/p>\n<\/td>\n | \n (Rs.) <\/b><\/p>\n<\/td>\n | \n ($) <\/b><\/p>\n<\/td>\n | \n (Rs.) <\/b><\/p>\n<\/td>\n | \n ($) <\/b><\/p>\n<\/td>\n | \n (Rs.) <\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n Revenues<\/b><\/p>\n<\/td>\n | \n 675<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 49,296<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 600<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 43,838<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 12<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 671<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 48,967<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 1<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nCost of Revenues\n<\/p>\n<\/td>\n | \n \n312\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n22,758\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n276\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n20,116\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n13\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n309\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n22,558\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n1\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n Gross Profit<\/b><\/p>\n<\/td>\n | \n 363<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 26,538<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 325<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 23,722<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 12<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 362<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 26,409<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 0<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n Operating Expenses<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nSelling, General & Administrative expenses\n<\/p>\n<\/td>\n | \n \n197\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n14,387\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n174\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n12,670\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n14\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n180\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n13,107\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n10\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nResearch and Development expenses\n<\/p>\n<\/td>\n | \n \n56\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n4,108\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n54\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n3,949\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n4\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n60\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n4,359\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n(6\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nImpairment of non-current assets\n<\/p>\n<\/td>\n | \n \n82\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n5,972\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n181\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n13,200\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n(55\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n11\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n781\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n665\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nOther operating income\n<\/p>\n<\/td>\n | \n \n(2\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(128\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(3\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(228\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(44\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(2\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(149\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(14\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n Results from operating activities<\/b><\/p>\n<\/td>\n | \n 30<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 2,199<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n (80<\/b><\/p>\n<\/td>\n | \n )<\/b><\/p>\n<\/td>\n | \n (5,869<\/b><\/p>\n<\/td>\n | \n )<\/b><\/p>\n<\/td>\n | \n –<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 114<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 8,311<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n (74<\/b><\/p>\n<\/td>\n | \n )<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n \nNet finance income\n<\/p>\n<\/td>\n | \n \n(7\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(493\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(6\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(419\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n18\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n(3\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(237\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n108\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nShare of profit of equity accounted investees\n<\/p>\n<\/td>\n | \n \n(2\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(151\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(2\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(176\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(14\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(1\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(73\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n107\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n Profit \/ (loss) before Income Tax<\/b><\/p>\n<\/td>\n | \n 39<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 2,843<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n (72<\/b><\/p>\n<\/td>\n | \n )<\/b><\/p>\n<\/td>\n | \n (5,274<\/b><\/p>\n<\/td>\n | \n )<\/b><\/p>\n<\/td>\n | \n –<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 118<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 8,621<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n (67<\/b><\/p>\n<\/td>\n | \n )<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n \nIncome Tax\n<\/p>\n<\/td>\n | \n \n36\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n2,645\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n6\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n423\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n525\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n14\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n998\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n165\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n Profit \/ (loss) for the period<\/b><\/p>\n<\/td>\n | \n 3<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 198<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n (78<\/b><\/p>\n<\/td>\n | \n )<\/b><\/p>\n<\/td>\n | \n (5,697<\/b><\/p>\n<\/td>\n | \n )<\/b><\/p>\n<\/td>\n | \n –<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 104<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 7,623<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n (97<\/b><\/p>\n<\/td>\n | \n )<\/b><\/p>\n<\/td>\n<\/tr>\n\n | \n | \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| \n Diluted Earnings Per Share (EPS)<\/b><\/p>\n<\/td>\n | \n 0.02<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 1.19<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n (0.47<\/b><\/p>\n<\/td>\n | \n )<\/b><\/p>\n<\/td>\n | \n (34.37<\/b><\/p>\n<\/td>\n | \n )<\/b><\/p>\n<\/td>\n | \n –<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 0.63<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 45.83<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n (97<\/b><\/p>\n<\/td>\n | \n )<\/b><\/p>\n<\/td>\n<\/tr>\n\n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n<\/table>\n\n\n| \n As % to revenues<\/b><\/p>\n<\/td>\n | | \n | \n | \n\n Q3 FY21<\/b><\/p>\n<\/td>\n | | \n\n Q3 FY20<\/b><\/p>\n<\/td>\n | | \n | \n\n Q2 FY21<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n \nGross Profit\n<\/p>\n<\/td>\n | | \n | \n | \n\n \n53.8\n<\/p>\n<\/td>\n | | \n\n \n54.1\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | | \n | \n\n \n53.9\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nSG&A\n<\/p>\n<\/td>\n | | \n | \n | \n\n \n29.2\n<\/p>\n<\/td>\n | | \n\n \n28.9\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | | \n | \n\n \n26.8\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nR&D\n<\/p>\n<\/td>\n | | \n | \n | \n\n \n8.3\n<\/p>\n<\/td>\n | | \n\n \n9.0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | | \n | \n\n \n8.9\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nEBITDA\n<\/p>\n<\/td>\n | | \n | \n | \n\n \n24.0\n<\/p>\n<\/td>\n | | \n\n \n24.5\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | | \n | \n\n \n25.9\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nPBT\n<\/p>\n<\/td>\n | | \n | \n | \n\n \n5.8\n<\/p>\n<\/td>\n | | \n\n \n(12.0\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | | \n | \n\n \n17.6\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nPAT\n<\/p>\n<\/td>\n | | \n | \n | \n\n \n0.4\n<\/p>\n<\/td>\n | | \n\n \n(13.0\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | | \n | \n\n \n15.6\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\n| \n EBITDA Computation<\/b><\/p>\n<\/td>\n<\/tr>\n\n | \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| \n Particulars<\/b><\/p>\n<\/td>\n | \n Q3 FY21<\/b><\/p>\n<\/td>\n | | \n | \n\n Q3 FY20<\/b><\/p>\n<\/td>\n | | \n | \n\n Q2 FY21<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n ($)<\/b><\/p>\n<\/td>\n | \n (Rs.)<\/b><\/p>\n<\/td>\n | | \n | \n\n ($)<\/b><\/p>\n<\/td>\n | \n (Rs.)<\/b><\/p>\n<\/td>\n | | \n | \n\n ($)<\/b><\/p>\n<\/td>\n | \n (Rs.)<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n Profit before Income Tax<\/b><\/p>\n<\/td>\n | \n \n39\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n2,843\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | | \n | \n\n \n(72\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(5,274\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | | \n | \n\n \n118\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n8,621\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nInterest income (net)*\n<\/p>\n<\/td>\n | \n \n(2\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(180\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | | \n | \n\n \n(4\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(274\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | | \n | \n\n \n(0\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n | \n \n(1\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nDepreciation\n<\/p>\n<\/td>\n | \n \n29\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n2,131\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | | \n | \n\n \n29\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n2,130\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | | \n | \n\n \n30\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n2,188\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nAmortization\n<\/p>\n<\/td>\n | \n \n15\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n1,086\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | | \n | \n\n \n13\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n955\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | | \n | \n\n \n15\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n1,084\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nImpairment\n<\/p>\n<\/td>\n | \n \n82\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n5,972\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | | \n | \n\n \n181\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n13,200\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | | \n | \n\n \n11\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n781\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n EBITDA <\/b><\/p>\n<\/td>\n | \n 162<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 11,851<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | | \n | \n\n 147<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 10,737<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | | \n | \n\n 174<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n 12,673<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n<\/table>\n * Includes income from Investments <\/i><\/p>\n All amounts in millions, except EPS. All US dollar amounts based on convenience translation rate of I USD = Rs. 73.01<\/i><\/p>\n\n\n| \n Key Balance Sheet Items<\/b><\/p>\n<\/td>\n<\/tr>\n\n | \n\n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n Particulars<\/b><\/p>\n<\/td>\n | \n As on 31st Dec
\n
2020 <\/b><\/p>\n<\/td>\n | \n As on 30th Sep
\n
2020 <\/b><\/p>\n<\/td>\n | \n As on 31st Dec
\n
2019 <\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n ($) <\/b><\/p>\n<\/td>\n | \n (Rs.) <\/b><\/p>\n<\/td>\n | \n ($) <\/b><\/p>\n<\/td>\n | \n (Rs.) <\/b><\/p>\n<\/td>\n | \n ($) <\/b><\/p>\n<\/td>\n | \n (Rs.) <\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n \nCash and cash equivalents and current investments\n<\/p>\n<\/td>\n | \n \n291\n<\/p>\n<\/td>\n | \n \n21,282\n<\/p>\n<\/td>\n | \n \n357\n<\/p>\n<\/td>\n | \n \n26,074\n<\/p>\n<\/td>\n | \n \n280\n<\/p>\n<\/td>\n | \n \n20,457\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nTrade receivables (current & non-current)\n<\/p>\n<\/td>\n | \n \n732\n<\/p>\n<\/td>\n | \n \n53,408\n<\/p>\n<\/td>\n | \n \n689\n<\/p>\n<\/td>\n | \n \n50,335\n<\/p>\n<\/td>\n | \n \n631\n<\/p>\n<\/td>\n | \n \n46,095\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nInventories\n<\/p>\n<\/td>\n | \n \n607\n<\/p>\n<\/td>\n | \n \n44,309\n<\/p>\n<\/td>\n | \n \n563\n<\/p>\n<\/td>\n | \n \n41,134\n<\/p>\n<\/td>\n | \n \n517\n<\/p>\n<\/td>\n | \n \n37,746\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nProperty, plant and equipment\n<\/p>\n<\/td>\n | \n \n771\n<\/p>\n<\/td>\n | \n \n56,263\n<\/p>\n<\/td>\n | \n \n754\n<\/p>\n<\/td>\n | \n \n55,026\n<\/p>\n<\/td>\n | \n \n722\n<\/p>\n<\/td>\n | \n \n52,709\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nGoodwill and Other Intangible assets\n<\/p>\n<\/td>\n | \n \n562\n<\/p>\n<\/td>\n | \n \n41,062\n<\/p>\n<\/td>\n | \n \n624\n<\/p>\n<\/td>\n | \n \n45,553\n<\/p>\n<\/td>\n | \n \n423\n<\/p>\n<\/td>\n | \n \n30,847\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nLoans and borrowings (current & non-current)\n<\/p>\n<\/td>\n | \n \n280\n<\/p>\n<\/td>\n | \n \n20,443\n<\/p>\n<\/td>\n | \n \n376\n<\/p>\n<\/td>\n | \n \n27,429\n<\/p>\n<\/td>\n | \n \n224\n<\/p>\n<\/td>\n | \n \n16,320\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nTrade payables\n<\/p>\n<\/td>\n | \n \n316\n<\/p>\n<\/td>\n | \n \n23,072\n<\/p>\n<\/td>\n | \n \n313\n<\/p>\n<\/td>\n | \n \n22,833\n<\/p>\n<\/td>\n | \n \n244\n<\/p>\n<\/td>\n | \n \n17,810\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nEquity\n<\/p>\n<\/td>\n | \n \n2,320\n<\/p>\n<\/td>\n | \n \n1,69,395\n<\/p>\n<\/td>\n | \n \n2,265\n<\/p>\n<\/td>\n | \n \n1,65,337\n<\/p>\n<\/td>\n | \n \n2,036\n<\/p>\n<\/td>\n | \n \n1,48,672\n<\/p>\n<\/td>\n<\/tr>\n | \n | \n\n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\n| \n Revenue Mix by Segment<\/b><\/p>\n<\/td>\n<\/tr>\n\n | \n\n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | | <\/tr>\n \n| \n Segment <\/b><\/p>\n<\/td>\n | \n Q3 FY21<\/b><\/p>\n<\/td>\n | \n Q3 FY20<\/b><\/p>\n<\/td>\n | \n YoY
\n
Gr % <\/b><\/p>\n<\/td>\n | \n Q2 FY21<\/b><\/p>\n<\/td>\n | \n QoQ
\n
Gr % <\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n (Rs.) <\/b><\/p>\n<\/td>\n | \n (Rs.) <\/b><\/p>\n<\/td>\n | \n (Rs.) <\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n Global Generics <\/b><\/p>\n<\/td>\n | \n 40,751<\/b><\/p>\n<\/td>\n | \n 35,927<\/b><\/p>\n<\/td>\n | \n 13 <\/b><\/p>\n<\/td>\n | \n 39,841<\/b><\/p>\n<\/td>\n | \n 2<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nNorth America\n<\/p>\n<\/td>\n | \n \n17,394\n<\/p>\n<\/td>\n | \n \n15,999\n<\/p>\n<\/td>\n | \n \n9\n<\/p>\n<\/td>\n | \n \n18,328\n<\/p>\n<\/td>\n | \n \n(5\n<\/p>\n<\/td>\n | \n \n)\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nEurope\n<\/p>\n<\/td>\n | \n \n4,143\n<\/p>\n<\/td>\n | \n \n3,093\n<\/p>\n<\/td>\n | \n \n34\n<\/p>\n<\/td>\n | \n \n3,754\n<\/p>\n<\/td>\n | \n \n10\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nIndia\n<\/p>\n<\/td>\n | \n \n9,591\n<\/p>\n<\/td>\n | \n \n7,636\n<\/p>\n<\/td>\n | \n \n26\n<\/p>\n<\/td>\n | \n \n9,123\n<\/p>\n<\/td>\n | \n \n5\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nEmerging Markets\n<\/p>\n<\/td>\n | \n \n9,623\n<\/p>\n<\/td>\n | \n \n9,199\n<\/p>\n<\/td>\n | \n \n5\n<\/p>\n<\/td>\n | \n \n8,636\n<\/p>\n<\/td>\n | \n \n11\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n Pharmaceutical Services and Active Ingredients (PSAI)<\/b><\/p>\n<\/td>\n | \n 7,009<\/b><\/p>\n<\/td>\n | \n 6,906<\/b><\/p>\n<\/td>\n | \n 1 <\/b><\/p>\n<\/td>\n | \n 8,505<\/b><\/p>\n<\/td>\n | \n (18<\/b><\/p>\n<\/td>\n | \n )<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n Proprietary Products & Others <\/b><\/p>\n<\/td>\n | \n 1,536<\/b><\/p>\n<\/td>\n | \n 1,005<\/b><\/p>\n<\/td>\n | \n 53 <\/b><\/p>\n<\/td>\n | \n 621<\/b><\/p>\n<\/td>\n | \n 147<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n| \n Total <\/b><\/p>\n<\/td>\n | \n 49,296<\/b><\/p>\n<\/td>\n | \n 43,838<\/b><\/p>\n<\/td>\n | \n 12 <\/b><\/p>\n<\/td>\n | \n 48,967<\/b><\/p>\n<\/td>\n | \n 1<\/b><\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n | \n | \n\n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | \n \n\u00a0\n<\/p>\n<\/td>\n | | \n | <\/tr>\n<\/table>\nRevenue Analysis<\/b><\/p>\n Global Generics (GG)<\/b><\/p>\n \nRevenues from GG<\/b> segment at Rs. 40.8 billion:\n<\/p>\n\n- \nYear-on-year growth of 13% and sequential quarter growth of 2%, primarily driven by new product launches and integration of the acquired portfolio from Wockhardt in India. The volume growth in the base business was largely offset by price erosion.\n<\/li>\n<\/ul>\n
North America<\/b><\/p>\n \nRevenues from North America<\/b> at Rs. 17.4 billion:\n<\/p>\n\n- \nYear-on-year growth of 9%, driven by new products launches, increase in volumes of our base business and a favorable forex rate, which was partially offset by price erosion.\n<\/li>\n
- \nSequential decline of 5%, primarily due to price erosion in some of the key molecules.\n<\/li>\n
- \nWe launched four new products during the quarter. This included Cinacalcet Tablets, Sapropterin Dihydrochloride Tablets and Succinylcholine Chloride Injection in the US along with Daptomycin Injection in Canada. We also re-launched one product in US – OTC Famotidine.\n<\/li>\n
- \nWe filed two new ANDAs during the quarter. As of 31st<\/sup> December 2020, cumulatively 89 generic filings are pending for approval with the USFDA (87 ANDAs and 2 NDAs under 505(b)(2) route). Of the 89 ANDAs, 48 are Para IVs and we believe 24 have \u2018First to File\u2019 status.\n<\/li>\n<\/ul>\n
Europe<\/b><\/p>\n \nRevenues from Europe<\/b> at Rs. 4.1 billion:\n<\/p>\n\n- \nYear-on-year growth of 34% and sequential growth of 10%, which were driven by new product launches, favorable forex movement and volume traction, offset partly by price erosion.\n<\/li>\n<\/ul>\n
India<\/b><\/p>\n \nRevenues from India <\/b>atRs. 9.6 billion:\n<\/p>\n\n- \nYear-on-year growth of 26% and sequential growth of 5%. YoY growth is on account of revenues from the acquired portfolio of Wockhardt and contribution from new product launches. QoQ growth was driven by volume traction.\n<\/li>\n<\/ul>\n
Emerging Markets<\/b><\/p>\n \nRevenues from Emerging Markets<\/b> at Rs. 9.6 billion. Year-on-year growth of 5%. Sequential growth of 11%:\n<\/p>\n\n- \nRevenues from Russia<\/b> at Rs. 4.5 billion. Year-on-year decline of 8% is primarily due to weakening Ruble. Sequential growth of 14% contributed by increased volumes\n<\/li>\n
- \nRevenues from other CIS countries and Romania<\/b> market at Rs. 2.1 billion. Year-on-year growth of 18% and sequential growth of 8% driven by both base business and new product launches.\n<\/li>\n
- \nRevenues from Rest of World (RoW)<\/b> territories at Rs. 3.0 billion. Year-on-year growth of 20% and sequential growth of 10% is due to volume traction in the base business and new product launches.\n<\/li>\n<\/ul>\n
Pharmaceutical Services and Active Ingredients (PSAI)<\/b><\/p>\n \nRevenues from PSAI<\/b> at Rs. 7.0 billion:\n<\/p>\n\n- \nYear-on-year growth of 1% driven by new products and favorable forex rate, offset by lower volumes for some products.\n<\/li>\n
- \nSequential decline of 18% on account of lower volumes of certain products.\n<\/li>\n
- \nDuring the quarter we filed DMF for five products in the US.\n<\/li>\n<\/ul>\n
Proprietary Products (PP) & Others<\/b><\/p>\n \nRevenues from PP & Others <\/b>at Rs. 1.5 billion:\n<\/p>\n\n- \nYear-on-year growth of 53% and sequential growth of 147%. The growth was driven by milestone income received for the compound AUR102.\n<\/li>\n<\/ul>\n
Income Statement Highlights:<\/b><\/p>\n\n- Gross profit <\/b>margin at 53.8%:\n
\n- \nDecline of 30 bps over previous year and 10 bps sequentially, which was primarily impacted due to price erosion and lower export benefits, partially offset by the milestone income received for the compound AUR102.\n<\/li>\n
- \nGross profit margin for GG and PSAI business segments are at 57.6% and 25.3% respectively.\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n
\n- SG&A expenses <\/b>at Rs. 14.4 billion, increased by 14% year-on-year primarily due to incremental costs post the integration of the acquired portfolio from Wockhardt in this year and increased freight expenses. Sequentially, it increased by 10% primarily due to pickup in sales & marketing activities in branded markets and increase in freight expenses.\n<\/li>\n
- Impairment charge <\/b>of Rs. 6.0 billion. In January, 2021 there has been an additional generic launch for the product Nuvaring\u00ae<\/sup>, which has led to a considerable erosion in the value of this product for us, and accordingly we have taken an impairment charge of Rs. 3.2 billion. In addition to this, considering the current market dynamics, we have taken an additional impairment charge of Rs. 2.8 billion on the intangibles pertaining to other products. We had an impairment charge of Rs. 13.2 billion in Q3 FY 20 and Rs. 781 million in Q2 FY21.\n<\/li>\n
- R&D expenses <\/b>at Rs. 4.1 billion. As % to revenues these are: Q3 FY21: 8.3% | Q2 FY 21: 8.9% | Q3 FY20: 9.0%. Our focus continues on building a healthy pipeline of new products across our markets including development of products pertaining to COVID-19 treatment.\n<\/li>\n
- Other operating income <\/b>at Rs. 128 million compared to Rs. 228 million in Q3 FY20.\n<\/li>\n
- Net Finance income <\/b>at Rs. 493 million compared to Rs. 419 million in Q3 FY20.\n<\/li>\n
- Profit before Tax <\/b>at Rs. 2.8 billion, which is 5.8% of revenues.\n<\/li>\n
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |